24-Hour Crisis Hotline: (877)SAFEGBC or (877)723-3422 Mental Health & Substance Abuse Issues

6502 Nursery Drive, Suite 100
Victoria, TX 77904
Fax: (361)578-5500
Regular Hours: M-Fri 8am - 5pm
Every 3rd Thurs of the Month - Extended Hours Until 7 pm

Medical Disorders
Basic InformationLookupsLatest News
AHA News: Women May Be More Willing Than Men to Donate OrgansDNA Sensor Can Spot When COVID Is ContagiousTrials Show COVID Vaccines Well Worth It for Cancer PatientsCDC Endorses Booster Shots for Millions of AmericansChildhood Trauma Linked With Higher Odds for Adult Neurological IllsStudy Probes Relationship Between Migraines and SleepCancer in Hispanics: Good News and BadFDA Approves Pfizer Booster Shots for Seniors, High-Risk AmericansU.S. to Buy 500 Million More COVID Vaccine Doses for Global DonationAntibodies to Early Strains of COVID May Not Fight New Variants: StudyPregnant Women Who Get COVID Vaccine Pass Antibodies to NewbornsCDC Expert Panel to Weigh In on Vaccine BoostersWhich Kids Are at Highest Risk From COVID?4 Out of 10 Adults With No Known Heart Disease Have Fatty Hearts: StudyBooster Dose of J&J COVID Vaccine Increases ImmunityPost-Stroke Rehab: There's a Sweet Spot in the TimingCommon Form of Liver Cancer on the Rise in Rural AmericaCOVID Has Killed More Americans Than the Spanish Flu Did in 1918Telemedicine Gets High Marks for Follow-Ups After SurgeryPandemic Tied to Declining Birth Rates for U.S., Much of EuropeStudy Spots People at High Risk of Severe Breakthrough COVIDReview of Booster Shots for Moderna, J&J Vaccines Just Weeks Away: FauciDelta Variant Now Fueling 99% of U.S. COVID CasesLower Dose of Pfizer COVID Vaccine Works Well in Young Children, Company SaysFDA Panel OKs Pfizer Booster Shot for  People 65 or Older, But Not YoungerLong-Haul COVID in Kids Typically Ends Within 3 Months: StudyPfizer, Moderna Vaccines Still Offer Good Protection Against Severe COVID: StudyTrial Into Antioxidant for Parkinson's Disease Yields Disappointing ResultsIs Flu Ready for a Comeback? Get Your ShotCommon Eye Conditions Tied to Higher Risk for DementiaDrug Might Stop Heart Trouble Linked to Sickle Cell AnemiaChild Obesity Rose Sharply During PandemicFDA Advisory Panel to Meet on COVID Booster ShotsStatin Cholesterol Drugs May Help Fight Ulcerative ColitisAHA News: Physical Activity Is Helpful After a Stroke, But How Much Is Healthy?Special 'Strategies' Can Help People With Parkinson's Walk, But Many Patients UnawareEven When Undergoing Treatment, People With MS Gain From COVID VaccinesNIH Spending Nearly $470 Million on Long-Haul COVID StudyHospitalizing the Unvaccinated Has Cost U.S. Nearly $6 BillionIn 16 States, 35% or More Residents Now Obese: CDCPet Store Puppies Passing Drug-Resistant Bacteria to PeopleIs a Combo COVID/Flu Shot on the Way?1 in 500 Americans Has Died From COVID-19Having Even a Cousin or Grandparent With Colon Cancer Raises Your Risk: StudyBlood Cancer Patients Could Benefit From COVID Booster Shot: StudyWHO Says Africa Will Get 30% of COVID Vaccines It Needs by FebruaryCOVID Vaccines for Kids Under 12 Could Come This Fall: FauciEbola Vaccine Effective in African Clinical TrialBritain OK's COVID Vaccine for Kids 12 and Older; Hopes to Avoid LockdownsIsraeli Data on COVID Boosters to Be Published This Week in Major Journal
Questions and AnswersLinks
Related Topics


One-Dose Blood Thinner Could Slash Blood Clot Risk After Knee Replacement

HealthDay News
by By Ernie Mundell and Robert Preidt HealthDay Reporters
Updated: Jul 20th 2021

new article illustration

TUESDAY, July 20, 2021 (HealthDay News) -- Anyone who's ever undergone knee replacement understands the real and troubling risk of post-op blood clots. Many patients are told take a daily blood thinner pill long after their procedure.

But a new study finds that a one-time injection of an experimental blood thinner called abelacimab may greatly reduce the odds for these clots in recovering knee replacement patients.

The researchers compared abelacimab with another prescription blood thinner called enoxaparin (brand name Lovenox) in 412 patients undergoing knee replacement.

Compared to enoxaparin, a single injection of abelacimab reduced the risk of blood clots by 80% for up to a month after surgery, and didn't increase the risk of bleeding — a common side effect with blood thinners.

"Patients who undergo knee replacement routinely receive anti-clotting treatment with enoxaparin or other anticoagulant medications that require daily administration," said research team leader Jeffrey Weitz. He's a hematologist and professor of medicine and of biochemistry and biomedical sciences at McMaster University in Hamilton, Canada. He's also executive director of the university's Thrombosis and Atherosclerosis Research Institute.

"With a single injection of abelacimab after surgery, we found much better protection against clots in the veins in the leg [deep vein thrombosis, or DVTs] compared with enoxaparin, one of the current standards of care," Weitz said in a McMaster news release.

The study was funded by Massachusetts-based Anthos Therapeutics, which is developing abelacimab. The report was published July 19 in the New England Journal of Medicine and also presented at a meeting of the International Society on Thrombosis and Haemostasis.

According to the research team, abelacimab is an antibody that binds to both the inactive and activated forms of a clotting factor called factor XI, preventing its activation and activity, and halting clot formation.

One expert unconnected to the study said the drug shows some promise.

"DVT formation is a significant fear in lower-extremity orthopedic surgery. This drug could be applied not only to total joint replacement, but also to fracture treatment. I'll look forward to further research," said Dr. Jeffrey Schildhorn, an orthopedic surgeon at Lenox Hill Hospital in New York City.

The treatment's convenience is also a huge plus, Schildhorn said. Patients only need the one-time injection and compliance should rise because they don't need to remember to take a daily blood thinner pill, he added.

Still, there are unanswered questions, Schildhorn said. What if rare cases of excessive bleeding arise when abelacimab is used?

"If excess bleeding occurs in some patients, are the effects of this medication reversible? What agents are used to reverse the anticoagulant effects [that might lead to bleeding], and how much time is required for the effects to wane?" he wondered. Only further research can help answer those questions, Schildhorn said.

For their part, the research team believes that the positive findings from their trial suggest that abelacimab may help treat other cardiovascular conditions.

For example, Weitz said, the drug might be used "for prevention of stroke in patients with atrial fibrillation and for treatment of deep-vein thrombosis and pulmonary embolism — clots in the veins of the leg and clots in the lung," and in cancer patients.

More information

The American Society of Hematology has more on blood clots.

SOURCES: Jeffrey Schildhorn MD, orthopedic surgeon, Lenox Hill Hospital, New York City; McMaster University, news release, July 19, 2021